Findings suggest Zilretta could potentially provide a cost-effective treatment option for patients with osteoarthritis of the knee BURLINGTON, Mass., May 22, 2017 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (NASDAQ: FLXN ) today announced the findings from a new health economics analysis of….